Navigation Links
Blood-thinning copycat enters malaria fight
Date:6/1/2010

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

Malaria is an infection of red blood cells that is transmitted by mosquitoes. The most common form of malaria is caused by the parasite Plasmodium falciparum which burrows into red blood cells where it rapidly multiplies, leading to massive numbers of parasites in the blood stream that can cause severe disease and death.

At the moment, all anti-malarials licensed for use in humans block the development of the parasite within the red blood cell.

But Dr James Beeson, Ms Michelle Boyle and Dr Jack Richards from the institute's Infection and Immunity division, along with colleagues at the Burnet Institute and Imperial College London, have identified a new approach that could stop the parasite infecting red blood cells in the first place.

Using real-time video microscopy of red blood cell infection, the team showed that heparin-like carbohydrates blocked the ability of the malaria parasite to infect cells, Dr Beeson said.

"The malaria parasite needs a protein called MSP1 if it is to infect red blood cells as MSP1 is involved in the initial attachment of the parasite to the cells," Dr Beeson said.

"We have shown that heparin-like carbohydrates bind to MSP1 which stops the parasite from properly attaching to the red blood cell and, therefore, from invading."

The findings are published today in the international journal Blood and have raised the prospect of developing new anti-malarials that are based on the structure and activity of heparin-like molecules.

Although humans produce heparin-like molecules naturally, they do not occur at high enough levels in the blood to have anti-malarial activity, Dr Beeson said. "Heparin itself wouldn't be suitable as an anti-malarial as it prevents blood clotting. However, we have identified related compounds that are more potent against malaria than heparin but do not prevent blood clotting- these could form the basis of new antimalarial drugs."

Each year more than 400 million people contract malaria, and around one million people, mostly children, die from the disease.


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. New blood-thinning drug safer than rat poison
2. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
3. DFG to establish 10 new collaborative research centers
4. US and UK research centers launch major collaboration on atmospheric research, technology
5. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
6. Weight Watchers vs. fitness centers
7. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Sicilian word enters British genetic language
10. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
11. Tellme Enters Automotive Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood-thinning copycat enters malaria fight
(Date:7/20/2017)... WASHINGTON , July 20, 2017 Delta (NYSE: ... to board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics ... Delta,s ... Delta Sky Club is now integrated into the boarding process to ...
(Date:5/16/2017)... 2017  Veratad Technologies, LLC ( www.veratad.com ), an ... identity verification solutions, announced today they will participate as ... 15 thru May 17, 2017, in Washington ... Center. Identity impacts the lives of ... quickly evolving digital world, defining identity is critical to ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced ... to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B ... to cross the cell membrane and bind intracellular STAT3 and inhibit its function. ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology: